By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dako A/S (Acquired by Agilent Technologies, Inc.) 

Produktionsvej 42

Glostrup    DK-2600  Denmark
Phone: 45-44-85-95-00 Fax: 45-44-85-95-95



Company News
Agilent (A) Launches New Panel For Fast FISH Testing On Dako (A) Omnis In Lung Cancer 9/22/2016 11:23:27 AM
Dako (A), an Agilent Technologies Inc. (A) Company, Announces Expanded Use Of PD-L1 Diagnostic Test In Europe 5/12/2016 10:36:42 AM
Dako (A), An Agilent (A) Company, Announces Availability Of New Lung Cancer Test In Europe 4/7/2016 11:33:20 AM
Dako (A) Snags Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma 1/25/2016 7:57:33 AM
Quest Diagnostics (DGX) Expands Dako (A)'s PD-L1 IHC 28-8 Complementary Test To Include Melanoma 1/25/2016 6:26:23 AM
Dako (A), An Agilent (A) Company, Announces FDA Approval Of New Test For Lung Cancer Patients 10/12/2015 10:59:44 AM
Quest Diagnostics (DGX) Introduces Dako (A)'s PD-L1 Complementary Diagnostic Test To Support Bristol-Myers Squibb (BMY)'s OPDIVO Anti-PD-1 Therapy For Non-Squamous Non-Small Cell Lung Cancer 10/12/2015 6:57:39 AM
Dako (A) Snags FDA Approval of New Companion Diagnostic for Lung Cancer 10/5/2015 6:59:24 AM
Quest Diagnostics (DGX) Introduces Dako (A)'s PD-L1 Companion Diagnostic For KEYTRUDA, Merck & Co. (MRK)'s Anti-PD-1 Therapy For Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Disease Progression On Or After Platinum-Containing Chemotherapy 10/5/2015 6:20:10 AM
Dako (A) Strikes Avelumab Pact with Pharma Giants Pfizer (PFE) and Merck & Co. (MRK) 9/25/2015 6:24:19 AM